Nature's Sunshine Products, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6390271012
USD
21.17
0.32 (1.53%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Nature's Sunshine Products, Inc. stock-summary
stock-summary
Nature's Sunshine Products, Inc.
Pharmaceuticals & Biotechnology
Nature's Sunshine Products, Inc. (NSP), together with its subsidiaries, is a natural health and wellness company. The Company is engaged in the manufacturing and direct selling of nutritional and personal care products. The Company has four business segments that are divided based on the various characteristics of their distributor bases, selling and distributor compensation plans, and product formulations, as well as the internal organization and business operations. Three business segments operate under the Nature's Sunshine Products brand. The China and New Markets segment also includes the Company's wholesale business, in which the Company sells its products to various locally managed entities independent of the Company. The fourth business segment operates under the Synergy WorldWide brand. Its line of over 700 products includes various product classifications, such as immune, cardiovascular, digestive, personal care, weight management and other general health products.
Company Coordinates stock-summary
Company Details
2901 W Blue Grass Blvd Ste 100 , LEHI UT : 84043-4189
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 43 Schemes (19.56%)

Foreign Institutions

Held by 30 Foreign Institutions (18.93%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. J. Christopher Teets
Independent Chairman of the Board
Mr. Terrence Moorehead
President, Chief Executive Officer, Director
Mr. Robert Mercer
Independent Director
Mr. Richard Moss
Independent Director
Ms. Mary Springer
Independent Director
Mr. Robert Straus
Independent Director
Ms. Heidi Wissmiller
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
115 Million
(Quarterly Results - Jun 2025)
Net Profit:
6 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 302 Million (Micro Cap)

stock-summary
P/E

26.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.49

stock-summary
Return on Equity

9.08%

stock-summary
Price to Book

1.92